|
|
|
ix | |
| Dedication |
|
xi | |
| Preface |
|
xiii | |
| Acknowledgments |
|
xviii | |
|
PART 1 Introduction to Pharmacologic Principles |
|
|
|
Chapter 1 Consumer Safety and Drug Regulations |
|
|
2 | (12) |
|
|
|
3 | (1) |
|
|
|
4 | (1) |
|
|
|
5 | (5) |
|
|
|
10 | (1) |
|
Health Care Professionals and the Law and Ethics |
|
|
10 | (1) |
|
|
|
11 | (3) |
|
Chapter 2 Drug Names and References |
|
|
14 | (12) |
|
|
|
15 | (1) |
|
|
|
16 | (3) |
|
Legal Terms Referring to Drugs |
|
|
19 | (1) |
|
Terms Indicating Drug Actions |
|
|
20 | (2) |
|
|
|
22 | (1) |
|
The Internet as Reference |
|
|
23 | (1) |
|
|
|
24 | (2) |
|
Chapter 3 Sources and Bodily Effects of Drugs |
|
|
26 | (18) |
|
|
|
27 | (2) |
|
|
|
29 | (1) |
|
Drug Processing by the Body (Pharmacokinetics) |
|
|
29 | (4) |
|
Other Variables Affecting Drug Action |
|
|
33 | (6) |
|
Unexpected Responses to Drugs |
|
|
39 | (3) |
|
|
|
42 | (2) |
|
Chapter 4 Medication Preparations and Supplies |
|
|
44 | (19) |
|
|
|
45 | (10) |
|
|
|
55 | (5) |
|
|
|
60 | (3) |
|
Chapter 5 Abbreviations and Systems of Measurement |
|
|
63 | (14) |
|
|
|
63 | (6) |
|
|
|
69 | (5) |
|
|
|
74 | (3) |
|
Chapter 6 Safe Dosage Calculations |
|
|
77 | (20) |
|
|
|
82 | (1) |
|
Method 1 Basic Calculation |
|
|
83 | (2) |
|
Method 2 Ratio and Proportion |
|
|
85 | (4) |
|
|
|
89 | (2) |
|
|
|
91 | (1) |
|
Prevention of Medication Errors |
|
|
91 | (1) |
|
|
|
92 | (5) |
|
Chapter 7 Responsibilities and Principles of Drug Administration |
|
|
97 | (13) |
|
Responsible Drug Administration |
|
|
97 | (2) |
|
|
|
99 | (1) |
|
Principles of Administration |
|
|
100 | (8) |
|
|
|
108 | (2) |
|
Chapter 8 Administration by the Gastrointestinal Route |
|
|
110 | (15) |
|
Administration of Medications Orally |
|
|
112 | (5) |
|
Administration of Medications Rectally |
|
|
117 | (1) |
|
Administration of Rectal Suppository |
|
|
118 | (1) |
|
Administration of Medications by Percutaneous Endoscopic Gastrostomy (PEG) or Nasogastric Tube (NGT) |
|
|
119 | (2) |
|
|
|
121 | (4) |
|
Chapter 9 Administration by Parenteral and Other Routes |
|
|
125 | (33) |
|
Sublingual and Buccal Administration |
|
|
126 | (1) |
|
Transcutaneous Drug Delivery System |
|
|
127 | (2) |
|
|
|
129 | (3) |
|
|
|
132 | (14) |
|
|
|
146 | (1) |
|
|
|
147 | (1) |
|
|
|
147 | (2) |
|
|
|
149 | (1) |
|
|
|
150 | (8) |
|
Chapter 10 Poison Control |
|
|
158 | (10) |
|
|
|
159 | (1) |
|
|
|
160 | (1) |
|
External Poisoning of Skin or Eyes |
|
|
161 | (1) |
|
Poisoning by Sting and Snakebite |
|
|
161 | (1) |
|
|
|
162 | (3) |
|
|
|
165 | (3) |
|
PART 2 Drug Classifications |
|
|
|
Chapter 11 Nutritional Concepts of Pharmacology |
|
|
168 | (36) |
|
|
|
170 | (4) |
|
|
|
174 | (8) |
|
|
|
182 | (10) |
|
|
|
192 | (1) |
|
|
|
193 | (7) |
|
|
|
200 | (2) |
|
|
|
202 | (2) |
|
Chapter 12 Integumentary System Medications |
|
|
204 | (21) |
|
|
|
205 | (1) |
|
|
|
206 | (1) |
|
Emollients and Protectants |
|
|
207 | (1) |
|
|
|
208 | (1) |
|
|
|
208 | (3) |
|
Scabicides and Pediculicides |
|
|
211 | (1) |
|
|
|
212 | (6) |
|
|
|
218 | (2) |
|
Agents Used to Treat Acne |
|
|
220 | (2) |
|
Cautions for Topical Medications |
|
|
222 | (1) |
|
|
|
223 | (2) |
|
Chapter 13 Autonomic Nervous System Drugs |
|
|
225 | (54) |
|
|
|
228 | (3) |
|
|
|
231 | (2) |
|
|
|
233 | (2) |
|
|
|
235 | (3) |
|
|
|
238 | (2) |
|
Chapter 14 Cardiovascular System Medications |
|
|
240 | (1) |
|
Cardiac Glycosides (Digoxin) |
|
|
241 | (3) |
|
|
|
244 | (7) |
|
|
|
251 | (2) |
|
|
|
253 | (4) |
|
|
|
257 | (4) |
|
|
|
261 | (5) |
|
|
|
266 | (6) |
|
|
|
272 | (1) |
|
|
|
273 | (3) |
|
|
|
276 | (3) |
|
Chapter 15 Urinary System Drugs |
|
|
279 | (20) |
|
|
|
279 | (6) |
|
|
|
285 | (4) |
|
|
|
289 | (1) |
|
|
|
290 | (1) |
|
|
|
291 | (2) |
|
Treatment of Benign Prostatic Hyperplasia |
|
|
293 | (4) |
|
|
|
297 | (2) |
|
Chapter 16 Gastrointestinal Drugs |
|
|
299 | (28) |
|
|
|
300 | (1) |
|
Agents for Treatment of Ulcers and Gerd |
|
|
301 | (3) |
|
|
|
304 | (3) |
|
Gi Antispasmodics or Anticholinergics |
|
|
307 | (1) |
|
Agents for Inflammatory Bowel Disease |
|
|
307 | (3) |
|
|
|
310 | (3) |
|
|
|
313 | (1) |
|
|
|
314 | (6) |
|
|
|
320 | (4) |
|
|
|
324 | (3) |
|
Chapter 17 Respiratory System Drugs and Antihistamines |
|
|
327 | (28) |
|
Respiratory Diseases and Disorders |
|
|
327 | (1) |
|
|
|
328 | (1) |
|
|
|
328 | (1) |
|
|
|
329 | (6) |
|
|
|
335 | (2) |
|
|
|
337 | (2) |
|
Mucolytics and Expectorants |
|
|
339 | (1) |
|
|
|
340 | (3) |
|
|
|
343 | (2) |
|
|
|
345 | (2) |
|
Safety of Cough-Cold-Allergy Products |
|
|
347 | (1) |
|
|
|
348 | (4) |
|
|
|
352 | (3) |
|
Chapter 18 Eye and Ear Medications |
|
|
355 | (19) |
|
|
|
355 | (2) |
|
|
|
357 | (3) |
|
|
|
360 | (6) |
|
|
|
366 | (1) |
|
|
|
367 | (1) |
|
|
|
368 | (4) |
|
|
|
372 | (2) |
|
Chapter 19 Central Nervous System Drugs: Analgesics. Sedatives, and Hypnotics |
|
|
374 | (24) |
|
|
|
374 | (14) |
|
|
|
388 | (2) |
|
|
|
390 | (6) |
|
|
|
396 | (2) |
|
Chapter 20 Psychotropic Medications, Alcohol, Drug Abuse, and Withdrawal treatment |
|
|
398 | (38) |
|
|
|
399 | (3) |
|
Selective Norepinephrine Reuptake Inhibitor (SNRI) for ADHD |
|
|
402 | (2) |
|
|
|
404 | (7) |
|
|
|
411 | (2) |
|
|
|
413 | (4) |
|
Antipsychotic Medications/Major Tranquilizers |
|
|
417 | (7) |
|
|
|
424 | (1) |
|
|
|
424 | (2) |
|
|
|
426 | (1) |
|
|
|
427 | (1) |
|
|
|
428 | (5) |
|
|
|
433 | (3) |
|
Chapter 21 Musculoskeletal and Anti-Inflammatory Drugs |
|
|
436 | (15) |
|
Skeletal Muscle Relaxants |
|
|
436 | (3) |
|
|
|
439 | (5) |
|
|
|
444 | (5) |
|
|
|
449 | (2) |
|
Chapter 22 Anticonvulsants. Antiparkinsonian Drugs, and Agents for Alzheimer's Disease |
|
|
451 | (21) |
|
|
|
451 | (3) |
|
Drug Therapy for Generalized and Partial Seizures |
|
|
454 | (2) |
|
Drug Therapy for Febrile Seizures |
|
|
456 | (1) |
|
Drug Therapy for Absence Seizures |
|
|
456 | (3) |
|
|
|
459 | (7) |
|
Agents for Restless Legs Syndrome |
|
|
466 | (1) |
|
Agents for Alzheimer's Disease |
|
|
467 | (3) |
|
|
|
470 | (2) |
|
Chapter 23 Endocrine System Drugs |
|
|
472 | (28) |
|
|
|
473 | (1) |
|
|
|
474 | (3) |
|
|
|
477 | (5) |
|
|
|
482 | (15) |
|
|
|
497 | (3) |
|
Chapter 24 Reproductive System Drugs |
|
|
500 | (27) |
|
|
|
500 | (1) |
|
|
|
501 | (2) |
|
Erectile Dysfunction Medications |
|
|
503 | (2) |
|
|
|
505 | (4) |
|
|
|
509 | (4) |
|
|
|
513 | (4) |
|
Drugs for Labor and Delivery |
|
|
517 | (5) |
|
|
|
522 | (3) |
|
|
|
525 | (2) |
|
Chapter 25 Anti-Infective Drugs |
|
|
527 | (36) |
|
|
|
528 | (1) |
|
|
|
529 | (1) |
|
|
|
529 | (1) |
|
|
|
530 | (2) |
|
|
|
532 | (1) |
|
|
|
533 | (1) |
|
|
|
534 | (1) |
|
|
|
535 | (1) |
|
|
|
536 | (3) |
|
|
|
539 | (1) |
|
|
|
540 | (1) |
|
|
|
541 | (2) |
|
|
|
543 | (3) |
|
Miscellaneous Anti-lnfectives |
|
|
546 | (2) |
|
|
|
548 | (2) |
|
|
|
550 | (1) |
|
|
|
551 | (2) |
|
|
|
553 | (2) |
|
Treatment of Human Immunodeficiency Virus /Aids Infections |
|
|
555 | (5) |
|
|
|
560 | (3) |
|
Chapter 26 Antineoplastic Drugs |
|
|
563 | (18) |
|
|
|
565 | (1) |
|
|
|
566 | (1) |
|
|
|
567 | (2) |
|
|
|
569 | (1) |
|
Hormones and Hormone Modifiers |
|
|
570 | (1) |
|
|
|
571 | (1) |
|
Colony-Stimulating Factors |
|
|
571 | (1) |
|
|
|
572 | (1) |
|
|
|
572 | (1) |
|
|
|
573 | (1) |
|
|
|
574 | (1) |
|
Cautions and Responsibilities for Antineoplastic Drugs |
|
|
574 | (5) |
|
|
|
579 | (2) |
|
Chapter 27 Age-Related Medication Issues |
|
|
581 | (32) |
|
Older Adult Considerations |
|
|
582 | (1) |
|
Physiologic Changes with Increasing Age |
|
|
582 | (3) |
|
Potentially Inappropriate Medication Use in Older Adults |
|
|
585 | (1) |
|
Drugs to Avoid with Certain Medical Conditions |
|
|
585 | (3) |
|
|
|
588 | (2) |
|
|
|
590 | (1) |
|
|
|
591 | (4) |
|
|
|
595 | (4) |
|
|
|
599 | (2) |
|
Comprehensive Exam for Part 1 |
|
|
601 | (6) |
|
Comprehensive Exam for Part 2 |
|
|
607 | (6) |
| Glossary |
|
613 | (14) |
| Index |
|
627 | |
